The Financial Comet
  • Business
  • World News
  • Politics
  • Investing
  • Business
  • World News
  • Politics
  • Investing

The Financial Comet

Politics

HHS SEC ROBERT F KENNEDY JR: American patients pay more so others can pay less — that stops now

by admin May 18, 2025
May 18, 2025
HHS SEC ROBERT F KENNEDY JR: American patients pay more so others can pay less — that stops now
NEWYou can now listen to Fox News articles!

President Donald Trump’s bold executive order on drug pricing isn’t just policy—it’s a revolution in healthcare affordability. The plan is simple yet transformative: ensure Americans pay no more for medications than citizens of other wealthy nations.

Consider this stark reality: a GLP-1 drug costing $88 in London commands $1,000 in the United States. Even after manufacturer discounts to insurers, Americans still pay over $400—for the identical medication, from the same company, produced in the same facility. This disparity is especially galling when pharmaceutical companies extract 70% of their profits from America—a nation representing just 4% of the world’s population. This global free-riding on American patients ends now.

Industry leaders recognize this imbalance. I’ve already engaged with CEOs from four major American pharmaceutical companies and a foreign manufacturer eager to relocate to the U.S. Their response has been encouraging, but we’re prepared to act decisively if necessary. U.S. Health and Human Services and Centers for Medicare & Medicaid Services (CMS) possess the statutory authority to deliver on President Trump’s commitment: other developed nations must pay more, so Americans can pay less, thus preserving the innovation pipeline.

Americans deserve both groundbreaking therapies and affordable access to them. Yet according to the Kaiser Family Foundation, nearly one-third of patients skip prescribed medications due to cost—an unacceptable reality in the world’s wealthiest nation.

While prevention through healthier lifestyles remains our best strategy for reducing medication dependence, certain treatments will always be essential. The pharmaceutical industry has delivered remarkable advancements in cancer and autoimmune therapies that benefit patients worldwide. 

We value continued innovation as a core American principle, but we cannot indefinitely subsidize global medical progress while other wealthy nations contribute disproportionately little.

President Trump’s negotiation approach has already proven effective with NATO, where European countries responded to accountability by making historic reinvestments that strengthened the alliance. The same principle applies here. The President and I stand united: global free riding on American patients must end.

CMS, with Dr. Mehmet Oz at the helm, extends beyond payment reform to fundamentally realigning care delivery incentives. This initiative will protect safety nets for vulnerable populations while addressing the financial pressures facing state partners and federal programs—particularly Medicaid, which has seen dramatic growth in both enrollment and costs.

The coming months will be decisive in achieving President Trump’s prescription for a healthier America—one where innovation thrives, and patients no longer shoulder an unfair share of the global healthcare burden.

This post appeared first on FOX NEWS

previous post
Middle East trip highlights President Donald Trump’s 17th week in office
next post
The popemobile, a signet ring and a ‘betrothal:’ How Pope Leo’s inauguration will unfold

Related Posts

Moscow returns body of Ukrainian journalist killed in...

May 1, 2025

‘He’s back’: Trump’s joint address to Congress to...

March 5, 2025

What’s the point of all these anti-DOGE lawsuits?...

March 2, 2025

Trump vindicated as explosive report confirms Iran supervises...

March 20, 2025

Canadians feel ‘under economic attack,’ frustration with US...

March 10, 2025

Trump reinstates ‘maximum pressure’ campaign against Iran

February 5, 2025

Republicans ready late-night session on Trump’s ‘big, beautiful...

May 19, 2025

Putin’s a ‘little bit scared’ of Trump as...

February 17, 2025

Trump says ‘something’s going to happen very soon’...

March 8, 2025

Kash Patel’s nomination to lead FBI faces first...

February 13, 2025

    Join our mailing list to get access to special deals, promotions, and insider information. Your exclusive benefits await! Enjoy personalized recommendations, first dibs on sales, and members-only content that makes you feel like a true VIP. Sign up now and start saving!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Editors’ Picks

    • 1

      Trump re-designates Iranian-backed Houthis as terrorists: ‘Threaten[s] security of American civilians’

      January 23, 2025
    • 2

      DeepSeek hit with large-scale cyberattack, says it’s limiting registrations

      January 28, 2025
    • 3

      Bank of America CEO says financial industry will jump into crypto payments if regulators allow it

      January 23, 2025
    • 4

      FDA officially authorizes Zyn nicotine pouches for sale following health review

      January 23, 2025
    • 5

      Universal’s ‘Wicked: For Good’ creates a unique marketing challenge

      January 27, 2025
    • 6

      UnitedHealthcare taps company veteran Tim Noel as new CEO following Brian Thompson killing

      January 27, 2025
    • 7

      Lara Trump to host weekend show on Fox News

      February 7, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting

    Disclaimer: thefinancialcomet.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 thefinancialcomet.com | All Rights Reserved